Skip to content

Study · Animal study (in vivo) · mouse · 1985

3 results

Modulation of polymorphonucleate-mediated cytotoxicity against Candida albicans by thymosin alpha 1.

Bistoni F, Baccarini M, Blasi E, Riccardi C, Marconi P, Garaci E

Thymus1 Jan 1985Cited by 6 (Europe PMC)

PMID3892779 (opens in a new tab)PepBankPUB-03892779
Publisher pageAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice, repeated thymosin alpha‑1 (100 micrograms/Kg s.c.) significantly increased circulating polymorphonuclear leukocytes in peripheral blood.

    In plain wordsIn mice, repeated thymosin alpha‑1 doses raised the number of circulating polymorphonuclear white blood cells.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseCirculating polymorphonuclear leukocyte number
    Study

    mousen: not reported in source

    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    100 micrograms/Kg · subcutaneous · doses 10, 8, 6, 4 and 2 days before the assayAs given in this study (mouse).

    Source sentences

    Summary
    the treatment with thymosin alpha 1 (100 micrograms/Kg s.c.) 10, 8, 6, 4 and 2 days before the assay may result in a significant numerical augmentation of circulating polymorphonucleates in the peripheral blood
    1 context sentence
    Summary · context
    In the present work we analyze the effects of thymosin alpha 1 treatment on the number and the candidacidal activity of murine polymorphonuclear leukocytes.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice, repeated thymosin alpha‑1 (100 micrograms/Kg s.c.) significantly increased the candidacidal activity of polymorphonuclear leukocytes in a 4-h cytotoxicity assay and a CFU inhibition assay.

    In plain wordsIn mice, repeated thymosin alpha‑1 doses made white blood cells better at killing Candida albicans in lab assays.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseCandidacidal activity of polymorphonuclear leukocytes after repeated dosing
    Study

    mousen: not reported in source

    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    100 micrograms/Kg · subcutaneous · doses 10, 8, 6, 4 and 2 days before the assayAs given in this study (mouse).

    Source sentences

    Summary
    as well as of their candidacidal activity when measured in vitro in both a 4-h cytotoxicity assay and a CFU inhibition assay against Candida albicans microorganisms.
    1 context sentence
    Summary · context
    In the present work we analyze the effects of thymosin alpha 1 treatment on the number and the candidacidal activity of murine polymorphonuclear leukocytes.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In mice, a single dose of thymosin alpha‑1 (500 micrograms/Kg s.c.) significantly decreased the candidacidal activity of polymorphonuclear leukocytes.

    In plain wordsIn mice, one higher dose of thymosin alpha‑1 lowered the ability of white blood cells to kill Candida albicans.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseCandidacidal activity of polymorphonuclear leukocytes after single high dose
    Study

    mousen: not reported in source

    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    500 micrograms/Kg · subcutaneous · single dose 3 days before the assayAs given in this study (mouse).

    Source sentences

    Summary
    On the other hand, a single dose of thymosin alpha 1 (500 micrograms/Kg s.c.) 3 days before the assay resulted in a significant decrease of the candidacidal activity of mouse polymorphonucleates.
    1 context sentence
    Summary · context
    In the present work we analyze the effects of thymosin alpha 1 treatment on the number and the candidacidal activity of murine polymorphonuclear leukocytes.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.